Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Shipments of Opana® ER will end September 1

    by
    • Optum Workers' Comp
    | Jul 26, 2017
    Tag Icon
    FDA
    In an ongoing efforts to monitor the removal of Opana® ER from the marketplace as requested by the FDA earlier this summer, Endo International plc confirmed they will cease manufacturing and shipping Opana ER (oxymorphone hydrochloride extended-release) by September 1, 2017.


  • FDA approves Vosevi™ for the treatment of chronic Hepatitis C virus infection

    by
    • Optum Workers' Comp
    | Jul 20, 2017
    Tag Icon
    Medication Plans, FDA
    The U.S. Food and Drug Administration (FDA) has approved a new fixed-dose, combination medication Vosevi™ to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.


  • California Releases Revised Drug Formulary Rule

    by
    • Optum Workers' Comp
    | Jul 19, 2017
    Tag Icon
    Formularies
    The California DWC released its revised drug formulary rule and opened a 15-day comment period expiring August 2, 2017. The rule contains some pertinent changes, summarized here.


  • CMS Expands Re-review Process

    by
    • Optum Workers' Comp
    | Jul 13, 2017
    Tag Icon
    CMS, MSA, Medicare Set-Aside
    The long awaited update to the Workers’ Compensation Medicare Set-Aside (WCMSA) Re-Review process, as promised by The Centers for Medicare and Medicaid Services (CMS) in late December 2016, has arrived.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.